Back to Headlines
Politics
Apr 23, 2026
Analyzed by GPT OSS 120B

US DOJ Reclassifies Select Marijuana Products to Schedule III, Paving Way for Research

AI Summary
The U.S. Department of Justice announced that certain state‑licensed medical marijuana products will be moved from Schedule I to Schedule III, a step that does not legalize recreational use but enables research and could reshape the industry. The move follows growing public support and forecasts a $47 billion market by 2026, with hearings slated for June.

DOJ Moves Select Marijuana Products to Schedule III

On Thursday, April 23, 2026, the U.S. Department of Justice clarified that state‑licensed medical marijuana will be shifted from the highly restrictive Schedule I category to Schedule III on the federal drug‑scheduling system. The change does not legalize recreational or broader medical use under federal law, but it lowers the barrier for scientific study.

Numbers Behind the Policy Shift

  • 57% of U.S. adults support full legalization of marijuana (Pew Research, 2024).
  • One in five Americans reported using marijuana in the past year (CDC).
  • Market researcher BDSA projects $47 billion in legal sales by 2026.

Why the Rescheduling Matters for Industry, Law Enforcement, and Patients

Moving products to Schedule III classifies them as having a "moderate to low potential for physical and psychological dependence," which:

  • Allows researchers to apply for federal approvals without the stringent hurdles of Schedule I.
  • Provides doctors with more reliable data on safety and efficacy, as highlighted by Acting Attorney General Todd Blanche.
  • Reduces the disparity between federal and state enforcement, addressing long‑standing concerns about disproportionate arrests.

Broader Economic and Political Implications

The decision aligns with a bipartisan trend toward loosening drug restrictions. It follows an executive order by former President Donald Trump and earlier steps by President Joe Biden that stalled before the end of his term. State markets, already legal in 40 states, may see increased investment as federal risk diminishes.

Future Outlook: Toward a Full Federal Reclassification?

Attorney General Blanche indicated that hearings on a broader reclassification will begin in June 2026. If successful, the federal stance could shift from a punitive model to one focused on public health and economic opportunity, potentially accelerating the projected $47 billion market growth.